drugset
drugset / Trial / NCT02089802

Optimizing Pazopanib Exposure in RCC Patients

NCT02089802 ↗

Phase 2 Terminated 6 enrolled Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e. OnkoDataMed GmbH · collab
NaSingle-groupOpen-labelTreatment

Summary

Optimization of Pazopanib Exposition in Patients with Renal Cell Carcinoma by Therapeutic Drug Monitoring followed by Individual Dose Escalation.

Timeline

Start
2014-02-25
Primary completion
2016-03-22
Completion
2016-03-22

Outcome

Outcome not reported

Stopped (Enrollment): “Early termination due to lack of recruitment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule 800 mg —

Indications

renal cell carcinoma